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Emerging biotechnologies pose public health challenges1 because of both the known and 
unforeseen risks they carry, the uncertain medical benefits they offer, the speed at which they 
have disseminated and their unproven mode of application.2 The development of therapies from 
advances in stem cell science reveals the need to pay critical attention to stem cell treatments. 
Stem cells have attracted scientific, clinical and public interest because they are self-renewing 
and have the capacity to develop into specific cell types, depending on the source of stem cells 
and their biological plasticity. The hope is that stem cells could be used either to replace 
damaged cells or to create an environment for cellular regeneration to treat several conditions, 
including osteoarthritis, diabetes, macular degeneration and Parkinson disease. 
Although promising in theory, so far very few stem cell therapies have proven to be safe 
and effective in clinical trials. Yet, despite the absence of evidence to support their use, there has 
been a global proliferation of clinics and associated businesses offering stem cell-based 
interventions to patients having serious medical conditions.3 These clinics operate mostly in the 
private health-care sector and typically market their interventions directly to patients over the 
Internet. The emergence of these clinics has not only created domestic markets in many high-
income countries,3 but has also fomented stem cell tourism – the movement of people across 
international boundaries to access putative stem cell treatments. The global reach of this 
expanding industry exploits weaknesses and differences in national regulatory infrastructures4 
and has revealed the need for an international approach to report and monitor the harms and 
benefits of these putative treatments. 
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Stem cell industry: limited oversight 
Although once limited to low-to-middle income countries with weak regulatory infrastructure, 
the stem cell industry has now penetrated high-income countries that have sophisticated 
biomedical regulatory systems.5 However, even in these otherwise highly regulated jurisdictions, 
providers of unproven stem cell therapies operate in an under-regulated domain – the grey zone 
between clinical practice, research and innovation. In some cases, these grey zones emerged 
because regulators introduced risk-based frameworks that excluded or exempted certain uses of 
stem cells from the mechanisms that regulate other biological and non-biological therapies. 
Regulators also accepted stem cell interventions as part of the standard practice of medicine. 
These regulatory weaknesses constitute a public health issue in at least three ways. First, 
many patients may be harmed by unproven stem cell therapies. While patients have the right to 
choose or refuse medical therapies that may carry significant risk, the validity of these choices 
depends on the information they have been given about the therapies and on their capacity to 
make informed choices. However, patients who seek stem cell interventions are often vulnerable 
and may be desperate for any treatment that they believe will save their life or improve its 
quality. They may also assume that such therapies are safe and effective, and trust not only that 
their medical providers are competent and have their best interests at heart, but also that these 
stem cell therapies are appropriately regulated. 
Second, because the industry is poorly regulated, it is subject to little public scrutiny and 
accountability. This lack of transparency enables clinicians to offer unproven and potentially 
unsafe therapies and to set their fees according to whatever the private health-care market will 
bear, without any form of regulatory or medical control. The interventions offered by stem cell 
providers can cost from 5000 United States Dollars (US$) to over US$ 100 000, not including 
travel expenses or follow-up care.4 For many patients unable to afford the high service fees, 
funding is sought through debt financing (e.g. mortgaging their house) or community and charity 
fundraising, among others. This may make patients financially vulnerable, have significant 
psychosocial consequences and deprive individuals and communities of resources that could be 
spent elsewhere. Additionally, in some countries, the costs of adverse health effects caused by 
stem cell interventions are borne by public health-care systems, not by stem cell clinics or 
patients. 
Third, regulatory failure not only enables unscrupulous providers to operate with little 
oversight, but also means that adverse effects are likely to be under-reported, as patients who are 
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harmed by failed stem cell interventions rarely seek legal redress. Because of this lack of 
oversight, patients harmed by these interventions –and their families– may also be affected 
financially; as well, objective data on the impact of this industry on patients and on public health 
systems may be incomplete. 
Therefore, failure to effectively regulate the stem cell industry may have a range of 
detrimental effects on patients, their families, public health systems, research and public trust in 
stem cell science and biomedical science in general. Given the local and global significance of 
these threats, it is important to consider the role of global organizations, particularly the World 
Health Organization (WHO), in regulating and containing the stem cell industry. 
International regulations 
The ethical, social and public concerns raised by stem cell interventions have prompted the 
International Society of Stem Cell Research (ISSCR), an international non-profit organization of 
stem cell scientists, to issue the Guidelines for Stem Cell Research and Clinical Translation.6 
While such voluntary guidelines are useful, they lack the political, legal and moral authority that 
guidelines from WHO may offer. Furthermore, if WHO were to adopt stem cell industry 
regulations under Article 21 of its Constitution, all Member States would be required to take the 
corresponding legislative steps unless they expressed reservations.7 This move would also help 
to strengthen national regulatory landscapes8 and assist sovereign governments to face potential 
political opposition to such regulation.9 
While some may question whether it is appropriate for WHO to engage in what might 
seem a highly specific scientific and clinical concern, Article 4 of the United Nations Education, 
Scientific and Cultural Organization (UNESCO) Universal Declaration on Bioethics and Human 
Rights10 recognizes that “In applying and advancing scientific knowledge, medical practice and 
associated technologies, human vulnerability should be taken into account. Individuals and 
groups of special vulnerability should be protected and the personal integrity of such individuals 
respected.”11 
The Declaration does not impose a positive duty on governments to mitigate every kind 
of human vulnerability. It does, however, emphasize the need for governments and the global 
community to be aware of the contexts where vulnerability arises and could be exploited, and to 
take measures to mitigate such exploitation. Article 14 (1) of the Declaration also provides that 
“The promotion of health and social development for their people is a critical purpose of 
government that all sectors of society share.” In regulatory context, this means that national 
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governments should regulate biomedical research and prevent fraud; this should be coupled with 
a coherent international response to promote the regulation of the clinical application, global 
production, sales and marketing of proven and unproven stem cell therapies. 
There is precedent for such action because WHO has previously addressed regulatory, 
governance and health issues associated with other health industries that run parallel to, or 
counter, established health systems and clinical practices. For example, following WHO 
Guidelines on developing consumer information on proper use of traditional, complementary 
and alternative medicines,12 some Member States have chosen to regulate practices and products 
of traditional, alternative and complementary medicines. 
If the adoption of regulations under Article 21 proved politically challenging, WHO 
could instead develop a code of practice drawn from the ISSCR guidelines. This would 
encourage sharing and gathering evidence on safety and efficacy before the commercial 
provision of stem cells, and clarify the ethical principles that should underpin national laws and 
regulations regarding clinical practice. 
Other possible roles for WHO might be to: provide much-needed technical guidance to 
resource-poor countries; use its mechanisms to gather and disseminate expert advice; convene 
expert advisory panels and committees on issues regarding the manufacture, licensing, regulation 
and proper use of stem cells; provide a platform for cross-jurisdiction information sharing; and 
establish a global governance framework for monitoring countries’ progress in regulating the 
stem cell industry. Such platform may encourage cross-country learning and help identifying and 
aligning best practices in the standards of care across jurisdictions. 
To tackle the issues associated to the national and international under-regulation of the 
stem cell industry, a global strategy needs to be put in place. This strategy, which could be 
developed by WHO, should moderate the global stem cell industry, protect global health and 
public safety and promote future research to increase the evidence base of the stem cell industry. 
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